Henry Schein, Inc. (NASDAQ:HSIC) Stock Has Consensus Target Price of $92.93 According to Brokerages

Henry Schein, Inc. (NASDAQ:HSIC) has been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $92.93.

Several research firms recently commented on HSIC. Citigroup reiterated a “buy” rating and issued a $112.00 target price (up from $100.00) on shares of Henry Schein in a research note on Wednesday, August 5th. UBS Group set a $94.00 price target on Henry Schein and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, August 21st. Piper Sandler upped their price objective on shares of Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Barclays reiterated an “overweight” rating and set a $100.00 price objective (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th.

Hedge Funds Weigh In On Henry Schein

A number of large investors have recently bought and sold shares of the stock. Operose Advisors LLC acquired a new position in shares of Henry Schein in the 2nd quarter valued at $33,000. Trust Co. of Vermont acquired a new stake in shares of Henry Schein during the 2nd quarter worth $42,000. Versant Capital Management Inc raised its position in shares of Henry Schein by 175.4% in the 2nd quarter. Versant Capital Management Inc now owns 617 shares of the company’s stock worth $52,000 after buying an additional 393 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Henry Schein by 167.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 936 shares of the company’s stock worth $69,000 after buying an additional 586 shares during the period. Finally, Contravisory Investment Management Inc. acquired a new position in Henry Schein in the second quarter valued at $84,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Down 1.2%

HSIC stock opened at $83.97 on Monday. The stock has a market capitalization of $9.36 billion, a P/E ratio of 24.48, a PEG ratio of 1.50 and a beta of 0.81. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. Henry Schein has a one year low of $61.94 and a one year high of $92.18. The company has a 50 day moving average price of $87.80 and a two-hundred day moving average price of $81.30.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The company had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. During the same quarter in the prior year, the company posted $1.10 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, sell-side analysts expect that Henry Schein will post 5.36 EPS for the current year.

About Henry Schein

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of health care products and services serving dental and medical professionals, laboratories, health care institutions and veterinary practices. The company operates primarily as a distributor, helping customers obtain medical, dental and veterinary supplies, equipment, pharmaceuticals and related products.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support practice management, clinical workflows, procurement, compliance and business operations.